Wick, A., Desjardins, A., Suárez García, C., Forsyth, P., Gueorguieva, I., Burkholder, T., . . . Rodon, J. (2020). Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Investigational new drugs, 38(5), . https://doi.org/10.1007/s10637-020-00910-9
Chicago Style (17th ed.) CitationWick, Antje, et al. "Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-beta Receptor I, in Combination with Standard Temozolomide-based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma." Investigational New Drugs 38, no. 5 (2020). https://doi.org/10.1007/s10637-020-00910-9.
MLA (9th ed.) CitationWick, Antje, et al. "Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-beta Receptor I, in Combination with Standard Temozolomide-based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma." Investigational New Drugs, vol. 38, no. 5, 2020, https://doi.org/10.1007/s10637-020-00910-9.